Search results | melanoma


Melanoma Partnering

The Melanoma Partnering provides understanding and access to the melanoma partnering deals and agreements entered into by the worlds leading healthcare companies.


Market research analysis: Monoclonal antibody partnering

A recent market research analysis of monoclonal antibody partnering has shown a high interest in partnering deals involving monoclonal antibody technology in the past few years

Industry trends in vaccine dealmaking – 2009 to 2014

Industry trends suggest that vaccine research and development is an increasingly active component of healthcare business development. In recent years there has been a significant increase in vaccine partnering and M&A activity.

Trends analysis: Cancer vaccine partnering on the rise

Recent trends analysis suggests that research in personalized medicine and vaccine development for disease treatment has increased partnering and collaboration in this arena. 


Celgene is a top pharmaceutical company, incorporated in Delaware and headquartered in Summit, New Jersey

Servier: Investing in and leading research like no other

Servier is a European research based pharmaceutical company focusing on the areas of oncology, cardiovascular and Central Nervous System diseases.

Celgene: Company Profile

Celgene, a top pharmaceutical company, is reviewed in terms of partnering, licensing and M&A interests and activity over recent years

Industry trends in vaccine dealmaking – 2007 to 2013

Industry trends suggest that vaccine research and development is an increasingly active component of healthcare business development. In recent years there has been a significant increase in vaccine partnering and M&A activity

Bristol-Myers Squibb eyes big deal, biotech rumour mill

Biotech rumour mill: If AstraZeneca, a big pharma company, decides it needs a big acquisition to get out of the doldrums, it may find itself competing with Bristol-Myers Squibb

Global pharma drug pipelines sees some light after years in doldrums

The global pharma drug industry productivity is finally improving after years of research disappointment, as drugmakers shift their focus from mass markets to making medicines for rarer, under-treated diseases

Biotech IPOs Start to Show Some Modest Signs of Life

Something feels wrong about putting the words “biotech” and “IPO” together in a headline. Th biotech IPOs market has been lifeless for so long that few investors even play the game anymore


Sorry, your search returned no results.


MedImmune and Immunocore partner for melanoma combinations

Immunocore will conduct a Phase Ib/II clinical trial combining checkpoint inhibitors MEDI4736 (anti-PD-L1) and/or tremelimumab (anti-CTLA-4) with IMCgp100

Pharma giants Pfizer and GSK biopharma partners for melanoma therapy

Pfizer biopharma partners with GSK for phase I/II study of combo melanoma therapy

Pfizer and Debiopharm collaborate to co-develop Tremelimumab in advanced melanoma

A co-development agreement to conduct a Phase 3 trial of tremelimumab (CP675,206), a fully human anti-CTLA4 monoclonal antibody for the treatment of patients with unresectable, Stage IV melanoma.

Merck and Syndax partner for cancer combo clinical

Syndax and Merck have entered into a clinical trial collaboration to evaluate the safety and efficacy of combining entinostat, an investigational epigenetic therapy, with KEYTRUDA

Array Biopharma regains binimetinib from Novartis

Array BioPharma has reached a definitive agreement with Novartis to regain full worldwide rights to binimetinib, a MEK inhibitor in three Phase 3 trials

BMS and Five Prime partner on Opdivo – FPA008 combination

Bristol-Myers Squibb and Five Prime Therapeutics have entered into an exclusive clinical collaboration agreement to evaluate the safety, tolerability and preliminary efficacy of combining Opdivo (nivolumab), Bristol-Myers Squibb’s investigational PD-1 (programmed death-1) immune checkpoint inhibitor, with FPA008

GE and GlaxoSmithKline form biotech partnering for tumour genetic disorder

GE Healthcare announced an biotech partnering agreement between its affiliate, Clarient Diagnostic Services and GlaxoSmithKline.

BMS and Ono Pharma have signed pharma alliance

Bristol-Myers Squibb and Ono Pharmaceutical have signed a strategic pharma alliance collaboration agreement to jointly develop and commercialize multiple immunotherapies.

BMS signs pharma partnering with Celldex

Bristol-Myers Squibb have entered into a pharma partnering with Celldex for combinational therapy for various cancers.

Merck forms pharma partnering with Amgen, Pfizer and Incyte

Merck  has signed three separate pharma partnering clinical collaboration agreements, through subsidiaries, with Amgen Inc., Incyte Corporation and Pfizer Inc. to evaluate novel combination regimens with MK-3475, Merck’s investigational anti-PD-1 immunotherapy.